[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3e02a3825ff50646b72bcf9defd00ba29509585920279a21abaa8c3af2243ac5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758905100,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136928050,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3e02a3825ff50646b72bcf9defd00ba29509585920279a21abaa8c3af2243ac5"
    }
  },
  {
    "ts": null,
    "headline": "Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol",
    "summary": "FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial showing Evkeeza, when added to standard lipid-lowering therapies, could lower LDL-C by about 50% compared to placebo in this high unmet need population TARRYTOWN, N.Y., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Reg",
    "url": "https://finnhub.io/api/news?id=a728243b773161286cb6a1063f4a622c284a3cc9192ec44ddecd01dfebf69fa1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758884400,
      "headline": "Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol",
      "id": 136892964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial showing Evkeeza, when added to standard lipid-lowering therapies, could lower LDL-C by about 50% compared to placebo in this high unmet need population TARRYTOWN, N.Y., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Reg",
      "url": "https://finnhub.io/api/news?id=a728243b773161286cb6a1063f4a622c284a3cc9192ec44ddecd01dfebf69fa1"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1",
    "summary": "Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1",
    "url": "https://finnhub.io/api/news?id=6cfbefbb48af104827fa6fc054bad111efde2d7ccad59e23af32d315159a981f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758871800,
      "headline": "Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1",
      "id": 136928051,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron: FDA Expands Evkeeza Approval to Children as Young as 1",
      "url": "https://finnhub.io/api/news?id=6cfbefbb48af104827fa6fc054bad111efde2d7ccad59e23af32d315159a981f"
    }
  }
]